Uplizna Amgen Australia Pty Ltd
Product name
Uplizna
Sponsor
Accepted date
May-2024
Active ingredients
inebilizumab
Proposed indication
For the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD).
Application type
A (new medicine)
Publication date
May-2024